Abstract
This article discusses research providing renewed reasons to revisit the utility of glutamatergic drugs for treating schizophrenia.
Bita Moghaddam
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
10.1126/science.281.5381.1349 · 1998
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
10.1152/jn.00875.2004 · 2005
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
10.1007/s00213-004-1982-8 · 2005
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial.
10.1038/nm1632 · 2007
Glutamate levels in medial prefrontal cortex according to illness phase of never-medicated individuals with psychosis.
10.1001/jamapsychiatry.2025.4091 · 2026
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
10.1016/j.neuron.2013.02.011 · 2013
Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
10.1038/s41586-022-04434-5 · 2022
GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.
10.1038/s41380-025-03279-4 · 2026
Grin2a knockout in adolescent dopamine neurons disrupts prediction error signaling and produces a phenotype relevant to schizophrenia.
10.1038/s41380-026-03632-1 · 2026
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
10.1016/j.biopsych.2015.03.016 · 2015
No additional external references are available.